RecruitingCerebral Amyloid Angiopathy
A Study of AMDX-2011P in Participants With CAA
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Sponsor: Amydis Inc.
You may qualify if…
- ✓ 1. Diagnosis of hereditary CAA or probable and definite symptomatic or asymptomatic sporadic CAA diagnosed through genetic testing or according to the modified Boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (MRI)prior to entry into study.
- ✓ 2. Abnormality consistent with CAA on historical MRI.
- ✓ 3. In general good health
You may not qualify if…
- ✕ 1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.
- ✕ 2. Clinically significant laboratory abnormalities assessed by the investigator.
- ✕ 3. Active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia.
- ✕ 4. Prolonged QTcF (\>450 ms for males and \>470 ms for females),cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.
Where it's recruiting
Arizona
Phoenix
Source: ClinicalTrials.gov · NCT05709314 · last updated 2026-02-13